2019 Packaging Pharmaceutical Manufacturing 
European Pharmaceutical Review
APRIL 10, 2025
This poses a significant challenge for pharmaceutical manufacturers, not least because of the technical challenges related to operations, supply chain and the environment. This article explores the potential impact of the proposal and considers how manufacturers can ensure the safety and reliability of their products.
European Pharmaceutical Review
JULY 25, 2022
Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. These may be mislabelled or produced in fake packaging and, most dangerously, there is no regulation around their manufacture. But what exactly does this look like? .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 8, 2025
Implementing PAT in (bio)pharmaceutical manufacturing New sensors or larger equipment with more complex setups (software and hardware) require stringent procedures to become fully implemented in a good manufacturing practice (GMP) manufacturing facility.
GMPSOP
JUNE 28, 2024
In the five years between 2019 and 2023, the FDA issued the following warning letters, closely related to ineffective deviation investigation. Adulterated Pharmaceuticals: 396 warnings iii. Packaging/labeling/Misbranding: 41 warnings vi. Many of those are direct results of ineffective or no-deviation investigations.
European Pharmaceutical Review
DECEMBER 21, 2022
2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.
European Pharmaceutical Review
AUGUST 10, 2023
Amidst numerous warning letters distributed by the US Food and Drug Administration (FDA) to pharmaceutical manufacturers in recent months, in July this year, the US regulatory body published its analysis on drug product quality in 2022. Eight FDA warning letters were handed to European companies in 2018.
pharmaphorum
JULY 21, 2021
According to the AP, around 40 states have now signed up to the national settlement package, which could be announced later today. From 1999–2019, nearly 500,000 people died from an overdose involving any opioid, including prescription and illicit opioids, according to figures from the US Centre for Disease Control and Prevention (CDC).
Expert insights. Personalized for you.
52 
Let's personalize your content